BioMimetic Therapeutics (BMTI) introduces Augmatrix™ Biocomposite Bone Graft Product Line
During the American Academy of Orthopedic Surgeons (AAOS) meeting
BMTI introduce Augmatrix™ Biocomposite Bone Graft, a new bone graft substitute product line, to surgeons and distributors.
- This Augmatrix product line is comprised of carbonate-apatite (calcium phosphate) and Type I collagen and is designed to be combined with bone marrow aspirate (BMA);
- The products are available in multiple forms to suit an array of bone grafting challenges, including fracture repair and general bone void filling procedures;
- The product line has been FDA cleared for use in orthopedic indications and is ready for sale in the US.
The Bottom Line: The Augmatrix product line will provide surgeons with a range of bone grafting solutions to procedures for which rhPDGF-BB offers, The Augmatrix bone graft substitute platform presents a complement to existing orthobiologics portfolio and will penetrate the large bone graft substitutes market earlier than anticipated. Aggregate sales of bone graft substitutes in the US are estimated to reach $1.7B in 2012.
- BMTI is trading flat at $2.24
Categories: BioMimetic Therapeutics (BMTI)
